Menu
Recruiting NCT07243873

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

— Observational Lung Cancer PET-CT

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PET-CT.
Who it may be relevant to
Registry conditions: Lung Cancer, PET-CT. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.

Interventions

  • Diagnostic test PET-CT
    A PET-CT scan is performed prior to initiating systemic treatment for the tumour.

Primary outcome measures

  • Structural similarity [Time frame: 2025.12.1-2026.12.1]
  • Peak Signal-to-Noise Ratio (PSNR) [Time frame: 2025.12.1-2026.12.1]
  • Structural Similarity Index (SSIM) [Time frame: 2025.12.1-2026.12.1]
  • Metabolic Parameter Consistency [Time frame: 2025.12.1-2026.12.1]
Secondary outcome measures (1)
  • predictive performance [Time frame: 2025.12.1-2026.12.1]

Eligibility criteria

Inclusion criteria

  • Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;
  • Voluntarily participate and sign an informed consent form;

Exclusion criteria

  • History of other malignant tumours;
  • Image artefacts;
  • Without pathological diagnostic information;
  • Without paired CT and FDG-PET scan images.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 5 centers
  • Affiliated Hospital of Zunyi Medical University — Zunyi
  • The First Affiliated Hospital of Nanchang University — Jiangxi
  • Shanghai East Hospital — Shanghai
  • Shanghai Pulmonary Hospital — Shanghai
  • Ningbo No.2 Hospital — Ningbo

Identifiers

NCT: NCT07243873 · PETgeneration

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗